NEW YORK (360Dx) – Interpace Diagnostics said this week that it has converted all of its remaining long-term secured outstanding debt into common stock. 

In March, the firm had announced that its outstanding secured debt arising from the acquisition of RedPath Integrated Pathology in 2014, and worth $9.34 million, was acquired for $8.9 million, or 95 percent of its face value, by an unnamed institutional investor. The deal involved a debt exchange for a $5.3 million secured convertible note and a $3.5 million secured note issued by Interpace.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.